Last update 01 Nov 2024

Mundipharma KK

Private Company|
Tokyo-to, Japan
|
www.mundipharma.co.jp

Overview

Tags

Other Diseases
Immune System Diseases
Hemic and Lymphatic Diseases
Small molecule drug
Radiolabeled antibody
Therapeutic radiopharmaceuticals

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Immune System Diseases3
Neoplasms3
Hemic and Lymphatic Diseases3
Nervous System Diseases1
Infectious Diseases1
Top 5 Drug TypeCount
Small molecule drug5
Therapeutic radiopharmaceuticals1
Radiolabeled antibody1
Top 5 TargetCount
κ opioid receptor x μ opioid receptor1
PNP(Purine nucleoside phosphorylase)1
CD20(B-lymphocyte antigen CD20)1
GABAA receptor(Gamma-aminobutyric acid A receptor)1
DHFR(Dihydrofolate reductase)1

Related

7
Drugs associated with Mundipharma KK
Remimazolam Besylate
Target
GABAA receptor
Mechanism
GABAA receptor agonists
Active Org.
PAION AGPAION AG [+4]
Originator Org.
PAION AGPAION AG
Active Indication
Sedation [+1]
Inactive Indication
Analgesia [+1]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date23 Jan 2020
Forodesine Hydrochloride
Target
PNP
Mechanism
PNP inhibitors [+1]
Active Org.
Mundipharma KK
Originator Org.
BioCryst Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc. [+1]
Active Indication
Peripheral T-Cell Lymphoma
Inactive Indication
Acute Lymphoblastic Leukemia [+12]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
JP
First Approval Date31 Mar 2017
Buprenorphine
Target
κ opioid receptor x μ opioid receptor
Mechanism
κ opioid receptor agonists [+1]
Active Org.
Indivior, Inc. [+7]
Originator Org.
OrphoMed, Inc.OrphoMed, Inc.Startup
Active Indication
Opioid-Related Disorders [+4]
Inactive Indication
Analgesia [+6]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date30 Jun 2010
22
Clinical Trials associated with Mundipharma KK
JPRN-jRCT2031200360 / CompletedPhase 2/3IIT
A Phase II/III Investigator Initiated Clinical Traial Evaluating the Efficacy and Safety of Remimazolam in Japanese Patients Undergoing Gastrointestinal Endoscopy
JPRN-JapicCTI-184109 / CompletedPhase 2
Phase II clinical study of leucovorin in combination with pralatrexate in Japanese relapsed/refractory peripheral T-cell lymphoma patients
JPRN-jRCT2080224048 / CompletedPhase 2
Phase II clinical study of leucovorin in combination with pralatrexate in Japanese relapsed/refractory peripheral T-cell lymphoma patients
100 Clinical Results associated with Mundipharma KK
Login to view more data
0 Patents (Medical) associated with Mundipharma KK
Login to view more data
100 Deals associated with Mundipharma KK
Login to view more data
100 Translational Medicine associated with Mundipharma KK
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 22 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Approved
6
1
Other
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free